Phase 3 Readout

VRCA: Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S

Name: Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S
Start: 2027-06-01
End: 2027-06-01

June 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: June 1, 2027
Company: Verrica Pharmaceuticals Inc. (VRCA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S

June 1, 2027

VRCA overview →

Company: Verrica Pharmaceuticals Inc. (VRCA)
Indication: Human Papilloma Virus (HPV); Warts; Common Warts